Join AAM | Association for Accessible Medicines
New Blog - Inflation Rebate Proposal Builds on Bad Policy for Generics
  • Alok Sonig – CEO, US Generics and Global Head, Generics R&D and Biosimilars, Lupin Pharmaceuticals
    “I’m a more effective CEO because I sit on the AAM board with my industry peers.”
    Alok Sonig
    CEO, US Generics and Global Head, Generics R&D and Biosimilars, Lupin Pharmaceuticals
  • Sanjeev Krishnan​ – President, North America, Glenmark Pharmaceuticals, Inc, USA
    “AAM membership is an investment in our business.”
    Sanjeev Krishan
    President, North America, Glenmark Pharmaceuticals, Inc, USA
  • “AAM is my ‘go-to’ source—just a phone call away—when I need information about a legislative issue.”
    Keren Haruvi
    President, Sandoz US, Head of North America
  • Aaron Mann – CEO, Kindeva Drug Delivery
    “AAM membership gives my company a voice on Capitol Hill and in state capitals across the country.”
    Aaron Mann
    CEO, Kindeva Drug Delivery
  • John Ducker – President and Chief Executive Officer, Fresenius Kabi USA, LLC
    “The association wrote formal comments to FDA rulemakings that represented our company’s views. This was very helpful.”
    John Ducker
    President and Chief Executive Officer, Fresenius Kabi USA, LLC
  • David Gaugh – Senior Vice President, Sciences & Regulatory Affairs, Association for Accessible Medicines
    “As a member of AAM, your regulatory and quality staff can be an integral voice on our member working groups.”
    David Gaugh
    Senior Vice President, Sciences & Regulatory Affairs, Association for Accessible Medicines
  • Lisa Parks – Vice President, Sciences & Regulatory Affairs, Association for Accessible Medicines
    “The Science & Regulatory team is your voice to connect with the FDA on policy, guidance and regulation matters.”
    Lisa Parks
    Vice President, Sciences & Regulatory Affairs, Association for Accessible Medicines

Join AAM

As the unifying and organizing force within the generics and biosimilars industry, AAM advocates on behalf of our members, supporting and protecting their ability to thrive and innovate.

Investing in AAM membership empowers you to chart a smart course for your business. New legislation and regulations are introduced all the time. Pressure is building to substantially revise supply chains. Brand-name manufacturers continue to use every tool at their disposal to retain monopoly rights past the original expiration date.​

About AAM Membership
About AAM Membership Flyer

When your company invests in AAM membership, we amplify your voice and advocate for your interests.

Benefits of membership include:

  • A seat at the table with other industry leaders to guide association priorities
  • Direct face-to-face interactions with key decision-makers and policymakers in DC
  • Access to the expertise of seasoned lobbyists and industry veterans​ 
  • Discounts on events and meetings​
  • Actionable information about the latest news and state of the industry

Join AAM, your association for generic and biosimilar medicines. No matter where you are in the product life cycle, AAM has a corporate membership option for you. Our team is here to assist in choosing the level of membership that makes sense, view AAM Membership Categories and Dues.

AAM membership is company based; AAM does not offer individual memberships. If you would like to sign up for our newsletter you can subscribe to our monthly AAM eNews or Biosimilars Bulletin.

One-year introductory memberships are now available for qualified organizations.​

Please fill out the form below to begin the process.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.